1. Home
  2. NMM vs NRIX Comparison

NMM vs NRIX Comparison

Compare NMM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navios Maritime Partners LP

NMM

Navios Maritime Partners LP

HOLD

Current Price

$69.14

Market Cap

2.0B

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$16.08

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMM
NRIX
Founded
2007
2009
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.6B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
NMM
NRIX
Price
$69.14
$16.08
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$30.58
AVG Volume (30 Days)
177.7K
1.1M
Earning Date
05-06-2026
04-10-2026
Dividend Yield
0.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,987,000.00
Revenue This Year
$5.57
N/A
Revenue Next Year
$3.66
$26.32
P/E Ratio
$7.24
N/A
Revenue Growth
N/A
99.31
52 Week Low
$28.37
$8.18
52 Week High
$74.21
$22.50

Technical Indicators

Market Signals
Indicator
NMM
NRIX
Relative Strength Index (RSI) 55.28 57.50
Support Level $49.57 $14.61
Resistance Level $68.82 $16.47
Average True Range (ATR) 2.55 0.93
MACD 0.31 0.17
Stochastic Oscillator 62.92 75.96

Price Performance

Historical Comparison
NMM
NRIX

About NMM Navios Maritime Partners LP

Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: